Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a vacuum device safely suck out dangerous heart clots? a global registry investigates

NCT ID NCT07769320

Knowledge-focused Sponsor: Charite University, Berlin, Germany Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study is a large international registry that will look back at the medical records of about 1,000 adults who were treated with the AngioVac system, a device that uses suction to remove blood clots, infected tissue, or other unwanted material from the heart and major blood vessels. The goal is to understand how safe and effective the device is in everyday clinical practice across a wide range of conditions, including heart infections and clots in the heart or lungs. By analyzing outcomes and complications, researchers hope to identify which patients benefit most and to develop best-practice recommendations for its use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AngioVac aspiration system (a device used to suction out unwanted material from blood vessels and heart chambers)
What this could lead to
If successful, this study could provide clearer guidance on when and how to use the AngioVac device, potentially improving outcomes for people with dangerous blood clots or heart infections.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by incomplete data or differences in how centers use the device.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients who underwent an AngioVac procedure during the specified and mentioned time period.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years at time of AngioVac procedure 2. Patient underwent percutaneous AngioVac aspiration (any AngioVac model or version used clinically during study period) 3. Procedure performed within study period (January 2018 (or site's institutional start date) - June 2026) 4. Written informed consent OR documented waiver/exemption from ethics authority (per local regulations per GDPR) Exclusion Criteria: 1. Insufficient documentation to assess primary safety or effectiveness endpoints (e.g. defined as \>20% missing data in core endpoint variables) 2. Patient objection to retrospective data use (where required by local law; GDPR Article 21 opt-out; honored without study impact) 3. Non-AngioVac procedures: Patients undergoing thrombus/vegetation removal by surgery or other percutaneous devices only (not AngioVac)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endocarditis infective are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial endocarditis endocarditis infective endocarditis pulmonary embolism thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endocarditis infective Endocarditis, bacterial Intracardiac mass Intracardiac thrombus Intravascular thrombosis Thrombus inferior vena cava Thrombus of pacemaker electrode Thrombus of pulmonary artery Thrombus of right atrium Thrombus of right ventricle Thrombus on catheter Vegetation on catheter Vegetation; endocarditis Vegetation; heart

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charité - Universitätsmedizin Berlin, Deutsches Herzzentrum der Charité, Department of Cardiothoracic and Vascular Surgery

    Berlin, 13353, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.